{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:50:37Z","timestamp":1791258637090,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007631","name":"Chungnam National University Hospital","doi-asserted-by":"publisher","award":["Research Fund 2025"],"award-info":[{"award-number":["Research Fund 2025"]}],"id":[{"id":"10.13039\/501100007631","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To compare clinical characteristics and visual outcomes according to recurrence timing in eyes with myopic choroidal neovascularization (CNV) following anti-vascular endothelial growth factor (anti-VEGF) therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included eyes with treatment-na\u00efve myopic CNV that achieved complete resolution after initial anti-VEGF therapy. To specifically evaluate the impact of recurrence timing, analyses were restricted to eyes that developed recurrence, which were categorized as early (&lt;\u200912 months) or late (\u2265\u200912 months). Baseline characteristics, multimodal imaging features, treatment profiles, and recurrence-specific parameters were compared. Longitudinal changes in best-corrected visual acuity (BCVA) were analyzed using linear mixed-effects models, and factors associated with the final BCVA were evaluated using multivariable linear regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 79 eyes, 32 (40.5%) experienced recurrence during the mean follow-up of 36.9\u2009\u00b1\u200923.7 months (early: 15 eyes; late: 17 eyes). The early recurrence group exhibited a significantly longer axial length (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.019); other baseline features and treatment profiles were similar between groups. At recurrence, subretinal hyperreflective material height was significantly greater in the late recurrence group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.041). Both groups showed visual improvement after initial treatment, without a significant difference in BCVA at any predefined time point. Baseline BCVA was the only independent predictor for final BCVA (\u03b2\u2009=\u20090.46,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.039); no significant association between recurrence timing and visual outcomes was detected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Visual outcomes were comparable between early and late recurrences of myopic CNV. Baseline BCVA was the strongest factor associated with long-term visual outcome, whereas no association between recurrence timing and visual outcomes was detected in this cohort.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-026-00900-8","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T09:33:54Z","timestamp":1783762434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recurrence timing and visual outcomes of recurrent myopic choroidal neovascularization after anti-VEGF therapy"],"prefix":"10.1186","volume":"12","author":[{"given":"Nala","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3558-008X","authenticated-orcid":false,"given":"Ki Young","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"issue":"5","key":"900_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.preteyeres.2012.04.001","volume":"31","author":"K Neelam","year":"2012","unstructured":"Neelam K, Cheung CM, Ohno-Matsui K, Lai TY, Wong TY. Choroidal neovascularization in pathological myopia. Prog Retin Eye Res. 2012;31(5):495\u2013525.","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"900_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","volume":"157","author":"TY Wong","year":"2014","unstructured":"Wong TY, Ferreira A, Hughes R, Carter G, Mitchell P. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol. 2014;157(1):9\u2013e2512.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"900_CR3","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","volume":"121","author":"S Wolf","year":"2014","unstructured":"Wolf S, Balciuniene VJ, Laganovska G, Menchini U, Ohno-Matsui K, Sharma T, Wong TY, Silva R, Pilz S, Gekkieva M. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. 2014;121(3):682\u2013e6921.","journal-title":"Ophthalmology"},{"issue":"6","key":"900_CR4","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","volume":"122","author":"Y Ikuno","year":"2015","unstructured":"Ikuno Y, Ohno-Matsui K, Wong TY, Korobelnik JF, Vitti R, Li T, Stemper B, Asmus F, Zeitz O, Ishibashi T. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study. Ophthalmology. 2015;122(6):1220\u20137.","journal-title":"Ophthalmology"},{"issue":"7","key":"900_CR5","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/eye.2012.97","volume":"26","author":"TY Lai","year":"2012","unstructured":"Lai TY, Luk FO, Lee GK, Lam DS. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye (Lond). 2012;26(7):1004\u201311.","journal-title":"Eye (Lond)"},{"issue":"11","key":"900_CR6","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1097\/IAE.0000000000001858","volume":"38","author":"NW Tan","year":"2018","unstructured":"Tan NW, Ohno-Matsui K, Koh HJ, Nagai Y, Pedros M, Freitas RL, Macfadden W, Lai TY. LONG-TERM OUTCOMES OF RANIBIZUMAB TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION IN EAST-ASIAN PATIENTS FROM THE RADIANCE STUDY. Retina. 2018;38(11):2228\u201338.","journal-title":"Retina"},{"issue":"10","key":"900_CR7","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1097\/IAE.0000000000002292","volume":"39","author":"Y Chen","year":"2019","unstructured":"Chen Y, Sharma T, Li X, Song Y, Chang Q, Lin R, Egger A, Foo A, Gekkieva M, Lai TYY. RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN ASIAN PATIENTS WITH MYOPIC CHOROIDAL NEOVASCULARIZATION: BRILLIANCE, a 12-Month, Randomized, Double-Masked Study. Retina. 2019;39(10):1985\u201394.","journal-title":"Retina"},{"issue":"9","key":"900_CR8","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1016\/j.ophtha.2013.06.010","volume":"120","author":"A Tufail","year":"2013","unstructured":"Tufail A, Narendran N, Patel PJ, Sivaprasad S, Amoaku W, Browning AC, Osoba O, Gale R, George S, Lotery AJ, et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology. 2013;120(9):1944\u2013e19451.","journal-title":"Ophthalmology"},{"issue":"7","key":"900_CR9","doi-asserted-by":"publisher","first-page":"e0271342","DOI":"10.1371\/journal.pone.0271342","volume":"17","author":"M Jain","year":"2022","unstructured":"Jain M, Narayanan R, Jana P, Mohamed A, Raman R, Verkicharla P, Padhy SK, Das AV, Chhablani J. Incidence, predictors and re-treatment outcomes of recurrent myopic choroidal neo-vascularization. PLoS ONE. 2022;17(7):e0271342.","journal-title":"PLoS ONE"},{"issue":"8","key":"900_CR10","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1097\/IAE.0b013e318285cc24","volume":"33","author":"HM Kang","year":"2013","unstructured":"Kang HM, Koh HJ. Ocular risk factors for recurrence of myopic choroidal neovascularization: long-term follow-up study. Retina. 2013;33(8):1613\u201322.","journal-title":"Retina"},{"key":"900_CR11","doi-asserted-by":"crossref","unstructured":"Ng DS, Kwok AK, Tong JM, Chan CW, Li WW. Factors influencing need for retreatment and long-term visual outcome after intravitreal bevacizumab for myopic choroidal neovascularization. Retina. 2015;35(12):2457-68.","DOI":"10.1097\/IAE.0000000000000610"},{"issue":"6","key":"900_CR12","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.ajo.2013.08.002","volume":"156","author":"HS Yang","year":"2013","unstructured":"Yang HS, Kim JG, Kim JT, Joe SG. Prognostic factors of eyes with na\u00efve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab. Am J Ophthalmol. 2013;156(6):1201\u2013e12102.","journal-title":"Am J Ophthalmol"},{"key":"900_CR13","doi-asserted-by":"publisher","first-page":"968800","DOI":"10.3389\/fmed.2022.968800","volume":"9","author":"R Jing","year":"2022","unstructured":"Jing R, Bo Y, Gao L, Wang Z. Factors associated with the recurrence of choroidal neovascularization in pathologic myopia. Front Med (Lausanne). 2022;9:968800.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"900_CR14","doi-asserted-by":"publisher","first-page":"e001150","DOI":"10.1136\/bmjophth-2023-001396","volume":"8","author":"AA Victor","year":"2023","unstructured":"Victor AA, Andayani G, Djatikusumo A, Yudantha AR, Hutapea MM, Ardhia SH, Suryoadji KA. Recurrence risk of myopic choroidal neovascularisation: a systematic review of current study. BMJ Open Ophthalmol. 2023;8(1):e001150.","journal-title":"BMJ Open Ophthalmol"},{"issue":"3","key":"900_CR15","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/IAE.0000000000003675","volume":"43","author":"M Ravenstijn","year":"2023","unstructured":"Ravenstijn M, Klaver CCW, Yzer S. LONG-TERM TREATMENT, OUTCOMES AFTER BEVACIZUMAB THERAPY FOR MACULAR NEOVASCULARIZATION IN WHITE PATIENTS WITH HIGH MYOPIA. Retina. 2023;43(3):444\u201353.","journal-title":"Retina"},{"issue":"10","key":"900_CR16","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3390\/ph14101042","volume":"14","author":"F Mallone","year":"2021","unstructured":"Mallone F, Giustolisi R, Franzone F, Marenco M, Plateroti R, Nebbioso M, Lambiase A, Gharbiya M. Ten-Year Outcomes of Intravitreal Bevacizumab for Myopic Choroidal Neovascularization: Analysis of Prognostic Factors. Pharmaceuticals (Basel). 2021;14(10):1047.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"8","key":"900_CR17","first-page":"1132","volume":"106","author":"E Borrelli","year":"2022","unstructured":"Borrelli E, Battista M, Vella G, Sacconi R, Querques L, Grosso D, Bandello F, Querques G. Three-year OCT predictive factors of disease recurrence in eyes with successfully treated myopic choroidal neovascularisation. Br J Ophthalmol. 2022;106(8):1132\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"900_CR18","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1136\/bjophthalmol-2021-318970","volume":"106","author":"S Xie","year":"2022","unstructured":"Xie S, Du R, Fang Y, Onishi Y, Igarashi T, Takahashi H, Kamoi K, Ohno-Matsui K. Dilated choroidal veins and their role in recurrences of myopic macular neovascularisations. Br J Ophthalmol. 2022;106(10):1429\u201335.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"900_CR19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1159\/000458160","volume":"237","author":"BG Moon","year":"2017","unstructured":"Moon BG, Cho AR, Lee J, Kim YJ, Lee JY, Kim JG, Yoon YH. Improved Visual Outcome and Low Recurrence with Early Treatment with Intravitreal Anti-Vascular Endothelial Growth Factor in Myopic Choroidal Neovascularization. Ophthalmologica. 2017;237(3):128\u201338.","journal-title":"Ophthalmologica"},{"issue":"11","key":"900_CR20","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.ophtha.2017.04.028","volume":"124","author":"CMG Cheung","year":"2017","unstructured":"Cheung CMG, Arnold JJ, Holz FG, Park KH, Lai TYY, Larsen M, Mitchell P, Ohno-Matsui K, Chen SJ, Wolf S, et al. Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management. Ophthalmology. 2017;124(11):1690\u2013711.","journal-title":"Ophthalmology"},{"issue":"17","key":"900_CR21","doi-asserted-by":"publisher","first-page":"5192","DOI":"10.3390\/jcm11175023","volume":"11","author":"D Allegrini","year":"2022","unstructured":"Allegrini D, Vezzola D, Borgia A, Raimondi R, Sorrentino T, Tripepi D, Stradiotto E, Al\u00ec M, Montesano G, Romano MR. OCT Analysis of Retinal Pigment Epithelium in Myopic Choroidal Neovascularization: Correlation Analysis with Different Treatments. J Clin Med. 2022;11(17):5192.","journal-title":"J Clin Med"},{"key":"900_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ajo.2015.11.014","volume":"162","author":"K Ohno-Matsui","year":"2016","unstructured":"Ohno-Matsui K, Jonas JB, Spaide RF. Macular Bruch Membrane Holes in Choroidal Neovascularization-Related Myopic Macular Atrophy by Swept-Source Optical Coherence Tomography. Am J Ophthalmol. 2016;162:133\u2013e1391.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"900_CR23","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/kjm2.12669","volume":"39","author":"DY Lee","year":"2023","unstructured":"Lee DY, Wu PY, Sheu SJ. Optical coherence tomography biomarkers for myopic choroidal neovascularization treated with anti-vascular endothelial growth factor. Kaohsiung J Med Sci. 2023;39(6):637\u201343.","journal-title":"Kaohsiung J Med Sci"},{"issue":"1","key":"900_CR24","doi-asserted-by":"publisher","first-page":"5431","DOI":"10.1038\/s41598-023-32417-7","volume":"13","author":"CJ Huang","year":"2023","unstructured":"Huang CJ, Hsia Y, Wang SW, Ma IH, Tsui MC, Hung KC, Ho TC. Characteristics and response of subretinal hyperreflective material to anti-vascular endothelial growth factor in myopic choroidal neovascularization. Sci Rep. 2023;13(1):5431.","journal-title":"Sci Rep"},{"issue":"4","key":"900_CR25","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000478030","volume":"238","author":"C Calvo-Gonz\u00e1lez","year":"2017","unstructured":"Calvo-Gonz\u00e1lez C, Reche-Frutos J, Fern\u00e1ndez-Vigo JI, S\u00e1enz-Franc\u00e9s F, Fern\u00e1ndez-P\u00e9rez C, Garc\u00eda-Feij\u00f3o J. Long-Term Outcomes of Two Different Initial Dosing Regimens of Intravitreal Ranibizumab Used to Treat Myopic Choroidal Neovascularization. Ophthalmologica. 2017;238(4):196\u2013204.","journal-title":"Ophthalmologica"},{"issue":"2","key":"900_CR26","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/ceo.13424","volume":"47","author":"S Li","year":"2019","unstructured":"Li S, Ding X, Sun L, Zhao X, Zhang A, Lyu C, Liu B, Zhang J, Jin C, Lu L. Two different initial treatment regimens of ranibizumab in myopic choroidal neovascularization: 12-month results from a randomized controlled study. Clin Exp Ophthalmol. 2019;47(2):250\u20138.","journal-title":"Clin Exp Ophthalmol"},{"issue":"4","key":"900_CR27","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00417-010-1599-z","volume":"249","author":"JM Ruiz-Moreno","year":"2011","unstructured":"Ruiz-Moreno JM, Montero JA, Amat-Peral P. Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses. Graefes Arch Clin Exp Ophthalmol. 2011;249(4):595\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"900_CR28","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1097\/IAE.0b013e3181f2a293","volume":"31","author":"T Wakabayashi","year":"2011","unstructured":"Wakabayashi T, Ikuno Y, Gomi F. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia. Retina. 2011;31(5):880\u20136.","journal-title":"Retina"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-026-00900-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00900-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00900-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:57:01Z","timestamp":1791255421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-026-00900-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["900"],"URL":"https:\/\/doi.org\/10.1186\/s40942-026-00900-8","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study adhered to the tenets of the Declaration of Helsinki and was approved by the Institutional Review Board of Chungnam National University Sejong Hospital (IRB No. 2025-12-010).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived due to the retrospective design of the study and anonymized data.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"135"}}